Portola Pharmaceuticals Inc. (PTLA)
Symbol Info
Listed Symbol PTLA
Name Portola Pharmaceuticals Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $40,130,000
Latest Fiscal EPS $-5.31
Price Info
21 Day Moving Average $27.7248
21 Day EMA $28.372390
50 Day Moving Average $27.0390
50 Day EMA $28.053120
200 Day EMA $29.467340
200 Day Moving Average 27.372550
52 Week High $37.95
52 Week Low $14.81
52 Week Change $18.881900
Alpha 0.000948
Beta 2.0600
Standard Deviation 0.166204
R2 0.184943
Periods 60
Share Information
10 Day Average Volume 2,246,370
20 Day Average Volume 1,513,487
30 Day Average Volume 1,259,671
50 Day Average Volume 1,171,521
Outstanding Shares 68,323,733
Float Shares 67,345,038
Percent Float 98.57%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 408
Institute Holdings Date 2019-07-31
Institute Bought Previous 3 Months 6,431,323
Institute Holdings Percent -
Institute Sold Previous 3 Months 11,732,857
Insider Holdings Date 2019-07-31
Insider Bought Previous 3 Months 12,311
Insider Holdings Percent 1.40%
Insider Sold Previous 3 Months 6,343
Insiders Shares Owned 978,695
Price Change
7 Day Price Change $-0.5300007
7 Day Percent Change -1.71%
21 Day Price Change $3.8600006
21 Day Percent Change 14.54%
30 Day Price Change $4.7299995
30 Day Percent Change 18.42%
Month To Date Price Change $3.7300
Month To Date Percent 13.98%
90 Day Price Change $-0.01
90 Day Percent Change -0.03%
Quarter To Date $3.280001
Quarter To Date Percent 12.09%
180 Day Price Change $-0.549999
180 Day Percent Change -1.78%
200 Day Price Change $3.959999
200 Day Percent Change 14.97%
Year To Date $10.889999
Year To Date Percent 55.79%
Profile
Description Portola Pharmaceuticals Inc is a biotechnology company focused on developing and commercializing novel therapeutics. The company focuses on areas of thrombosis, other hematologic disorders, and inflammation for patients who have limited or no approved treatment options. Portola focuses on biomarker or genetic approaches to clinical development that it believes will increase the probability of clinical, regulatory, and commercial success of first-in-class therapies. The company also uses collaborative agreements.
Details
Issue Type CS
Market Cap $2,077,724,721
Sec Type EQS
Auditor Ernst & Young LLP
Total Shares Outstanding 68,323,733
CEO Scott Garland
Employees 324
Last Audit UE
Classification
CIK 0001269021
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 270 East Grand Avenue
South San Francisco, CA 94080
Website https://www.portola.com
Facisimile +1 650 246-7376
Telephone +1 650 246-7000
Email IR@portola.com
Key Ratios
Profitability
EBIT Margin -349.2
EBITDA Margin -343.9
Pre-Tax Profit Margin -1,240
Profit Margin Cont -
Gross Margin 64.00
Profit Margin TOT -
Income Statements
Revenue $80,068,000
Revenue Per Share $1.1719
Revenue 3 Years $28.81
Revenue 5 Years $41.98
Valuation Measures
PE Ratio -
Enterprise Value $2,103,236,331
Price To Sales 25.949503
Price To Free Cash -7.9
PE High Last 5 Years -
Price To Book 3,510.5
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book -641.6
Financial Strength
Total Debt To Equity 491.5
Int Coverage -10.3
Current Ratio 3.6
Leverage Ratio 5.3
Quick Ratio 3.5
Long Term Debt To Capital 1.00
Assets
Receivables Turnover 4.0
Invoice Turnover 6.70
Assets Turnover 0.10
Management Effectiveness
Return Assets -69.21
Return On Equity -278.74
Return On Capital -81.37
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
PTLA
Portola Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.